Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Mather Group LLC.

Mather Group LLC. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,099 shares of the medical research company’s stock after purchasing an additional 163 shares during the quarter. Mather Group LLC.’s holdings in Thermo Fisher Scientific were worth $1,645,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in TMO. Linden Thomas Advisory Services LLC increased its stake in Thermo Fisher Scientific by 8.8% in the third quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company’s stock valued at $783,000 after purchasing an additional 125 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Thermo Fisher Scientific by 17.7% during the third quarter. Harbor Capital Advisors Inc. now owns 1,241 shares of the medical research company’s stock worth $628,000 after acquiring an additional 187 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in Thermo Fisher Scientific by 0.8% during the third quarter. Commonwealth Equity Services LLC now owns 99,703 shares of the medical research company’s stock worth $50,467,000 after acquiring an additional 835 shares during the last quarter. FAS Wealth Partners Inc. increased its stake in Thermo Fisher Scientific by 7.8% during the third quarter. FAS Wealth Partners Inc. now owns 748 shares of the medical research company’s stock worth $378,000 after acquiring an additional 54 shares during the last quarter. Finally, RMR Wealth Builders acquired a new stake in Thermo Fisher Scientific during the third quarter worth about $722,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on TMO shares. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Evercore ISI increased their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Barclays increased their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft raised their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $606.76.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $576.87 on Tuesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The business has a 50-day moving average of $574.18 and a two-hundred day moving average of $531.06. The stock has a market capitalization of $220.20 billion, a P/E ratio of 37.00, a P/E/G ratio of 2.41 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,277 shares of company stock worth $29,649,264. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.